Why Eli Lilly is Targeting Nav1.8 and MNK for Next-Gen Pain Therapeutics

In June 2026, Eli Lilly acquired 4E Therapeutics, strategically integrating a portfolio of oral mitogen-activated protein kinase–interacting kinase (MNK) inhibitors into its neuroscience pipeline ^[1]. The deal came soon after Lilly's 2025 acquisition of SiteOne Therapeutics and its Nav1.8 inhibitor program, reinforcing the company's two-pronged strategy for developing peripherally acting, non-opioid pain therapies ^[2]. The broader significance of these acquisitions extends far beyond a single company replenishing its pain pipeline after the discontinuation of clinical programs targeting the P2X7 and somatostatin 4 (SSTR4) receptors ^[3]. Instead, it signals an industry-wide paradigm shift: a deliberate pivot toward molecular mechanisms positioned precisely at the nexus of nociceptor hyperexcitability.

By targeting Nav1.8 at the level of action-potential electrogenesis and MNK–eIF4E signaling at the level of activity-dependent protein translation and neuronal plasticity, the field is beginning to address both the immediate and sustained dimensions of pathological pain.

Figure 1. 4E Therapeutics was acquired by Eli Lilly ^[4].

The Heterogeneity of Pain and the "Target Graveyard"

In reality, nociceptive, neuropathic, inflammatory, and nociplastic pain may produce similar symptoms while arising from very different mechanisms, including peripheral hyperexcitability, immune activation, spinal plasticity, and altered central processing. This heterogeneity helps explain why an analgesic may succeed in one indication but fail in another, and why a promising target may not translate clinically without selecting patients whose disease is driven by that pathway.

As a result, non-opioid pain programs have faced high clinical attrition, creating a so-called "target graveyard." Beyond Nav1.8 and MNK, many candidates have struggled to deliver both meaningful efficacy and an acceptable safety profile. Peripheral restriction has become an important strategy for reducing nociceptive signaling while avoiding cognitive, respiratory, and reward-related effects in the central nervous system. However, restricting a drug to the periphery does not guarantee clinical success.

Figure 2. The development of non-opioid treatments is necessary to replace opioid treatments.

Nav1.7 illustrates this challenge. Although loss-of-function variants in SCN9A cause congenital insensitivity to pain, selective Nav1.7 inhibitors have repeatedly failed to provide broad analgesic benefit. Possible reasons include incomplete channel inhibition, state-dependent pharmacology, limited exposure in relevant neuronal compartments, and the inability of small molecules to reproduce the effects of lifelong genetic loss ^[5].

Neuroimmune targets such as P2X7 face a different problem: their relevance depends strongly on cell type, inflammatory status, and disease stage. Without selecting patients who show active purinergic signaling, even a potent inhibitor may appear ineffective.

Figure 3. Schematic illustration of the pathogenic roles of the P2X7R in various models of NP ^[6].

The same principle applies to validated neuropeptide pathways such as CGRP and PACAP ^[7]. Success requires precise alignment among the ligand, receptor subtype, anatomical site, patient population, and therapeutic format.

Conversely, targets such as TRPV1 and the NGF–TrkA pathway have been limited by safety concerns. Systemic TRPV1 antagonists reduced thermal pain but caused on-target hyperthermia and impaired heat perception in clinical trials ^[8]. Anti-NGF antibodies showed meaningful analgesic activity in osteoarthritis but were constrained by reports of rapidly progressive joint damage ^[9]. These outcomes highlight a central challenge in pain drug development: pain also serves a protective function, and excessive suppression of warning signals may lead patients to overuse already damaged tissues.

Nav1.8 and MNK: Addressing the Spatial and Temporal Dimensions of Pain

In sharp contrast to the mechanistic hurdles that derailed earlier programs, Nav1.8 and MNK have emerged as leading candidates by occupying distinct, highly actionable positions within nociceptor biology. Rather than representing a generic search for a universal "pain switch," these targets address distinct temporal layers of hypersensitivity: signal propagation and sustained molecular plasticity.

Nav1.8, encoded by SCN10A, has advanced closest to clinical success among peripheral ion channel targets. As a tetrodotoxin-resistant sodium channel highly expressed in peripheral sensory neurons, it sits at a final common step of action-potential electrogenesis and repetitive firing, particularly under neuropathic and inflammatory conditions. Selective inhibition of Nav1.8 can profoundly reduce the propagation of nociceptive signals into the spinal cord without causing the broad sodium channel blockade that would impair cardiac, skeletal muscle, or central neuronal functions. The regulatory validation of suzetrigine (VX-548) for acute postoperative pain in 2025 provided definitive human pharmacological proof-of-concept for this approach, although its application in chronic, transcriptionally driven pain states remains an area of ongoing investigation.

Figure 4. Mechanism of action of suzetrigine ^[10].

While Nav1.8 interventions silence the moment-to-moment electrical activity of a neuron, MNK inhibition remains an actively pursued strategy due to its compelling mechanistic rationale for dismantling the chronification of pain. Following nerve injury or inflammation, nociceptors alter the activity-dependent translation of mRNAs encoding crucial receptors, ion channels, and intracellular signaling proteins. MNK1 and MNK2, which are activated downstream of the ERK and p38 mitogen-activated protein kinases, phosphorylate the cap-binding protein eIF4E to orchestrate these pathological translational programs. Preclinical genetic and pharmacological studies demonstrate that this MNK–eIF4E axis is inextricably linked to injury-induced mechanical hypersensitivity and persistent nociceptor excitability. Thus, targeting MNK represents a disease-modifying strategy intended to weaken the underlying molecular processes that sustain long-term neuronal sensitization.

Figure 5. Proposed MNK–eIF4E signaling mechanism in chronic pain ^[11].

Raising the Standard for Preclinical Translation: The Infrastructure Behind the Next-Gen Pipeline

The strategic pivot by industry leaders like Eli Lilly toward precision targets such as Nav1.8 and MNK fundamentally raises the standard for preclinical evidence. A statistically significant reduction in a singular, evoked reflex-withdrawal assay is no longer sufficient to justify clinical advancement. Today, competing in this space requires a robust infrastructure that can seamlessly connect pharmacokinetics, target engagement, and multidimensional disease-relevant phenotypes.

Cyagen serves as a critical enabler in this translational race, providing the advanced genetic engineering and comprehensive preclinical pharmacology platforms required to validate these next-generation pain therapeutics.

Cyagen's leadership is anchored by our advanced HUGO-GT™ (Humanized Genomic Ortholog for Gene Therapy) technology. Unlike traditional transgenic models that rely on random insertion, our proprietary platform generates the hSCN10A(Nav1.8)(SD) rat model via highly precise in situ genomic replacement.

Why this matters: This ensures the humanized SCN10A target remains under endogenous regulatory control. For biopharma developers, this preserves physiological expression patterns, offering unparalleled precision when evaluating the pharmacology, efficacy, and safety of clinical-stage Nav1.8 inhibitors.

Figure 6. Time-course analgesic effect of VX-548 on mechanical allodynia in the SNL model of hSCN10A(Nav1.8)(SD) rats.

This precision genetic modeling is seamlessly integrated with Cyagen's diverse portfolio of highly complementary, disease-relevant systems. Spanning peripheral nerve injury, spinal nerve injury, and chemotherapy-induced peripheral neuropathy, the company provides the mouse chronic constriction injury (CCI) model, the rat spinal nerve ligation (SNL) model, and cisplatin-induced pain models.

A Comprehensive Portfolio of Disease-Relevant Pain Models

To rigorously validate novel candidates like MNK inhibitors across distinct pain etiologies, Cyagen seamlessly integrates precision genetics with highly complementary neurological disease models:

Peripheral Nerve Injury (The mouse CCI model): Utilizes controlled sciatic-nerve constriction to robustly generate peripheral neuropathic phenotypes, ideal for evaluating cold and mechanical hypersensitivity.

Spinal Nerve Ligation (The rat SNL model): Generates stable mechanical allodynia via L5 ligation. Our internal validation confirms exceptional sensitivity, with gabapentin effectively restoring withdrawal thresholds and normalizing stride length and weight-bearing.

Chemotherapy-Induced Peripheral Neuropathy (Cisplatin-induced model): Reliably reproduces the longitudinally measurable mechanical and cold hypersensitivity characteristic of chemotherapy-induced peripheral neuropathy, rendering it highly suitable for the long-term evaluation of analgesic candidates.

By combining complementary pain models, researchers can determine whether a novel candidate, such as an MNK inhibitor targeting sustained neural plasticity, is effective across multiple injury mechanisms or best suited to a specific pain etiology. Cyagen supports this multidimensional evaluation through customizable preclinical pharmacology packages, covering model induction, efficacy testing, biomarker analysis, and figure-ready reporting.

Behavioral assessment extends beyond conventional evoked pain tests. Cyagen offers electronic von Frey testing for mechanical sensitivity, ethanol stimulation and cold-plate assays for cold sensitivity, and hot-plate, tail-flick, and Hargreaves assays for thermal sensitivity. Open-field testing, rotarod assessment, and gait analysis help identify motor impairment and functional changes, while spontaneous behaviors such as facial grooming provide less stimulus-dependent measures of pain.

Figure 7. Behavioral pain test results in the CCI model.

To connect analgesic efficacy with pharmacokinetic, pharmacodynamic, and biomarker data, Cyagen provides western blotting, ELISA, immunohistochemistry, qPCR, fluorescence imaging, and customized tissue collection. These capabilities can confirm target engagement, including changes in eIF4E phosphorylation following MNK inhibition.

The next generation of analgesics will depend not only on novel targets, but also on matching the right mechanism to the right pain condition, confirming target engagement in the relevant neural compartment, and generating robust preclinical evidence that translates across heterogeneous patient populations. Investment in Nav1.8 and MNK programs reflects this shift away from a universal pain switch and toward targeted therapies addressing distinct biological mechanisms of nociception. Through advanced genomic models, comprehensive pain assays, and integrated molecular analysis, Cyagen provides a translational platform for more precise and clinically relevant pain drug discovery.

👉 View Our Comprehensive Neuropathic Pain Model Validation Data Package

👉 Consult Our Neurobiology Experts to Design Your Assay

Reference

[1] 4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic Pain [press release]. Austin, TX: 4E Therapeutics; June 16, 2026. Available from: https://www.prnewswire.com/news-releases/4e-therapeutics-acquired-by-lilly-to-advance-non-opioid-approach-to-chronic-pain-302800631.html

[2] Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics [press release]. Indianapolis, IN: Eli Lilly and Company; May 27, 2025. Available from: https://www.prnewswire.com/news-releases/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics-302465735.html

[3] Manalac T. Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program. BioSpace. 2025 Oct 31. Available from: https://www.biospace.com/drug-development/lilly-refines-pain-pipeline-again-scrapping-mid-stage-program

[4] 4E Therapeutics [Internet]. Austin, TX: 4E Therapeutics, Inc.; [cited 2026 Jul 16]. Available from: https://4etherapeutics.com/

[5] MacDonald DI, Sikandar S, Weiss J, Pyrski M, Luiz AP, Millet Q, Emery EC, Mancini F, Iannetti GD, Alles SRA, Arcangeletti M, Zhao J, Cox JJ, Brownstone RM, Zufall F, Wood JN. A central mechanism of analgesia in mice and humans lacking the sodium channel NaV1.7. Neuron. 2021 May 5;109(9):1497-1512.e6. doi: 10.1016/j.neuron.2021.03.012. Epub 2021 Apr 5. PMID: 33823138; PMCID: PMC8110947.

[6] Chen D, Zhang S, Guo Y, Zhao X, Mao P, Hai X, Yang Z, Zhao G. P2X7 Receptor as a Therapeutic Target for Neuropathic Pain: From Mechanisms to Translational Strategies. Curr Pain Headache Rep. 2026 May 19;30(1):71. doi: 10.1007/s11916-026-01511-6. PMID: 42151670.

[7] Ashina M, Doležil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021 Jan;41(1):33-44. doi: 10.1177/0333102420970889. Epub 2020 Nov 24. PMID: 33231489; PMCID: PMC7786389.

[8] Rowbotham MC, Nothaft W, Duan RW, Wang Y, Faltynek C, McGaraughty S, Chu KL, Svensson P. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain. 2011 May;152(5):1192-1200. doi: 10.1016/j.pain.2011.01.051. Epub 2011 Mar 4. PMID: 21377273.

[9] Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, Verburg KM. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020 Jun;79(6):800-810. doi: 10.1136/annrheumdis-2019-216296. Epub 2020 Mar 31. PMID: 32234715; PMCID: PMC7286052.

[10] Pham A, Yep H, Wozniak S, Javvaji A, Nada E, Bergese S. Beyond Opioids: A Review of Suzetrigine for Acute Pain Management. Int J Mol Sci. 2025 Oct 10;26(20):9865. doi: 10.3390/ijms26209865. PMID: 41155158; PMCID: PMC12563693.

[11] 4E Therapeutics. Our Approach to Treating Neuropathic Pain [Internet]. Austin, TX: 4E Therapeutics, Inc.; [cited 2026 Jul 16]. Available from: https://4etherapeutics.com/approach/